Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial

BACKGROUND: Chronic hepatitis C (CHC) Patients, infected with genotype (GT) 2 or 3 are treated with Peg-IFN and ribavirin (RBV) (800 mg/day) for 24 weeks. Treatment duration can be shortened to 12-16 weeks if a higher dose of RBV (1.000/1.200 mg/day) was used without considerable loss of responsiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Maieron, Andreas, Metz-Gercek, Sigrid, Scherzer, Thomas-Matthias, Laferl, Hermann, Fischer, Gabriele, Bischof, Martin, Gschwantler, Michael, Ferenci, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141520/
https://www.ncbi.nlm.nih.gov/pubmed/21714878
http://dx.doi.org/10.1186/1756-0500-4-220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141520/
https://www.ncbi.nlm.nih.gov/pubmed/21714878
http://dx.doi.org/10.1186/1756-0500-4-220

Ejemplares similares